HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced that Dr. Alireza Faridar, Assistant Professor of Neurology at Houston Methodist and Weill Cornell Medical College, will give an oral presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Disease held in Lisbon, Portugal between March 5-9, 2024.

HOUSTON-（BUSINESS WIRE）-Coya Therapeutics，Inc。（纳斯达克股票代码：Coya）（“Coya”或“公司”），一家开发多种治疗平台的临床阶段生物技术公司，旨在增强Treg功能，包括生物制剂和今天，休斯顿卫理公会和威尔康奈尔医学院神经病学助理教授Alireza Faridar博士宣布，将于2024年3月5日至9日在葡萄牙里斯本举行的第18届阿尔茨海默病和帕金森病国际会议上发表口头报告。

Details and Registration for the conference are found here..

会议的详细信息和注册信息可在此处找到。。

Dr. Faridar and team are currently conducting a double-blind, randomized, well-controlled study in 38 AD patients evaluating the safety and tolerability, biological activity, blood and cerebrospinal fluid biomarkers, neuroimaging, and changes in cognitive function of LD IL-2 compared to placebo at pre-specified timepoints over the course of a 21-week treatment period and at 9 weeks after the last dose of study treatment..

Faridar博士及其团队目前正在对38名AD患者进行一项双盲，随机，良好对照研究，评估安全性和耐受性，生物活性，血液和脑脊液生物标志物，神经影像学，在21周治疗期和最后一剂研究治疗后9周的预定时间点，LD IL-2与安慰剂相比认知功能的变化。。

Topline results of this study are anticipated to be reported in the first half of 2024. The study is funded by the Gates Foundation and the Alzheimer’s Association.

预计这项研究的顶线结果将在2024年上半年报告。该研究由盖茨基金会和阿尔茨海默氏症协会资助。

About Alzheimer’s Disease

关于阿尔茨海默病

Alzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for up to 80% of dementia cases, affecting an estimated 5.7 million Americans. In more than 90% of people with Alzheimer’s, symptoms do not appear until after age 60.

阿尔茨海默病是痴呆症最常见的原因，痴呆症是记忆丧失和其他严重到足以干扰日常生活的认知能力的总称。阿尔茨海默氏病占痴呆症病例的80%，估计影响570万美国人。在超过90%的阿尔茨海默病患者中，症状直到60岁以后才会出现。

The incidence of the disease increases with age and doubles every 5 years beyond age 65. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment.

该病的发病率随着年龄的增长而增加，每65岁以后每5年增加一倍。阿尔茨海默病是一种进行性疾病，痴呆症状多年来逐渐恶化。在早期阶段，记忆丧失是轻微的，但对于晚期阿尔茨海默氏症，个体失去了进行对话和应对环境的能力。

It is the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older. On average, a person with Alzheimer's lives 4 to 8 years after diagnosis but can live as long as 20 years, depending on other factors. 1,2.

它是所有成年人中第六大死因，也是65岁或65岁以上人群的第五大死因。平均而言，阿尔茨海默病患者在诊断后4至8年内存活，但根据其他因素，其寿命可长达20年。1,2.

References

工具书类

Alzheimer’s Association (www.alz.org).

阿尔茨海默氏症协会（www.alz.org）。

Centers for Disease Control and Prevention (www.cdc.gov)

疾病控制和预防中心（www.cdc.gov）

About Coya Therapeutics, Inc.

关于Coya Therapeutics，Inc。

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya Therapeutics，Inc.（纳斯达克股票代码：Coya）总部设在德克萨斯州休斯顿，是一家临床阶段生物技术公司，开发专有治疗方法，专注于调节性T细胞（“Tregs”）的生物学和潜在治疗优势，以针对全身炎症和神经炎症。功能失调的Tregs是许多疾病的基础，包括神经退行性疾病，代谢性疾病和自身免疫性疾病，这种细胞功能障碍可能导致持续的炎症和氧化应激，导致免疫系统缺乏稳态。

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers.

Coya的研究产品候选管道利用多种治疗方式，旨在恢复Tregs的抗炎和免疫调节功能。Coya的治疗平台包括Treg增强生物制剂，Treg衍生的外泌体和自体Treg细胞疗法。Coya的300系列候选产品Coya 301和Coya 302是旨在增强Treg功能和扩大Treg数量的生物疗法。

COYA 301 (LD IL-2) is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers and is currently being investigated in AD, and COYA 302 (LD-IL-2 plus CTLA4 lg) is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages currently being investigated in amyotropic lateral sclerosis (ALS).

COYA 301（LD IL-2）是一种用于皮下给药的细胞因子生物制剂，旨在增强Treg功能并扩大Treg数量，目前正在AD中进行研究，COYA 302（LD-IL-2加CTLA4 lg）是用于皮下和/或静脉内给药的生物组合，旨在增强Treg功能，同时消耗T效应功能和目前正在肌萎缩侧索硬化症（ALS）中研究的活化巨噬细胞。

These two mechanisms may be additive or synergistic in suppressing inflammation. For more information about Coya, please visit www.coyatherapeutics.com.

这两种机制在抑制炎症方面可以是相加的或协同的。有关Coya的更多信息，请访问www.coyatherapeutics.com。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities.

本新闻稿包含基于我们管理层的信念和假设以及管理层当前可用信息的“前瞻性”声明。前瞻性声明包括除本演示文稿中包含的历史事实声明以外的所有声明，包括有关我们当前和未来财务绩效，业务计划和目标，当前和未来临床和临床前开发活动，我们正在进行和计划的时间和成功的信息临床试验和相关数据，我们的临床试验和相关数据的公告，更新和结果的时间，我们获得和维持监管批准的能力，我们产品候选人的潜在治疗效益和经济价值，竞争地位，行业环境和潜在的市场机会。

The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements..

“相信”，“可能”，“将会”，“估计”，“继续”，“预期”，“打算”，“期望”等词语旨在确定前瞻性陈述。。

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; ; and our estimates regarding expenses, future revenue, capital .

前瞻性陈述受已知和未知风险，不确定性，假设和其他因素的影响，包括但不限于与COVID-19影响相关的风险；我们的候选产品开发活动以及正在进行和计划中的临床试验的成功，成本和时间安排；我们计划开发和商业化靶向治疗药物；在我们的临床前或临床试验中患者登记和给药的进展；我们的产品候选人在临床试验中达到适用终点的能力；我们产品候选人的安全概况；我们的临床试验数据支持营销应用的潜力，以及这些事件的时间安排；我们为我们的运营获得资金的能力；我们的候选产品的开发和商业化；获得和维持监管部门批准的时间和能力；我们的产品候选人的市场接受率和临床效用；市场对我们产品候选人的规模和增长潜力，以及我们为这些市场服务的能力；我们的商业化，营销和制造能力和战略；与第三方就我们的候选产品商业化达成的未来协议；我们对获得和维护知识产权保护能力的期望；我们对第三方制造商的依赖；竞争疗法或产品的成功或可能变得可用；我们吸引和留住关键科学或管理人员的能力；我们能够确定具有显着商业潜力的其他候选产品，符合我们的商业目标；以及我们对费用，未来收入，资本的估计。

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

我们的这些前瞻性陈述主要基于我们目前对未来事件和趋势的预期和预测，我们认为这些预期和预测可能会影响我们的财务状况，运营成果，业务战略，短期和长期业务运营和目标，以及财务需求。

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

而且，我们的经营环境竞争激烈，变化迅速，新的风险可能会不时出现。我们的管理层不可能预测所有风险，我们也无法评估所有因素对我们业务的影响，或者任何因素或因素组合可能导致实际结果与任何因素中包含的结果大不相同我们可能会做出的前瞻性声明。

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur.

鉴于这些风险，不确定性和假设，本文讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果产生重大不利影响。尽管我们的管理层认为我们的前瞻性陈述中反映的期望是合理的，但我们不能保证前瞻性陈述中描述的未来结果，活动水平，绩效或事件以及情况将会实现或发生。

We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise..

我们不承担任何义务公开更新可能由于新信息，未来发展或其他原因而不时发布的任何前瞻性声明，无论是书面声明还是口头声明。。